Surmodics | SRDX - Kapitał Własny I Rezerwy





Kapitał Własny I Rezerwy Zmiana Data
Abbott USD 52.06B 69M 2026-03
Align Technology USD 4.05B 91.69M 2025-12
Anika Therapeutics USD 133.9M 9.56M 2026-03
Arrowhead Research USD 568.42M 102.37M 2025-12
Artivion USD 448.23M 9.54M 2025-12
Baxter International USD 6.04B 86M 2026-03
Boston Scientific USD 25.86B 1.63B 2026-03
EDAP TMS EUR 23.32M 4.5M 2025-09
Edwards Lifesciences USD 10.34B 132.6M 2025-12
Haemonetics USD 911.45M 62.28M 2025-12
Heron Therapeutics USD 13.28M 1.6M 2025-12
J&J USD 81.19B 358M 2026-03
Merit Medical Systems USD 1.63B 42.42M 2026-03
Mesa Laboratories USD 186.69M 8.22M 2025-12
Nektar Therapeutics USD 89.83M 4.75M 2025-12
Option Care Health USD 1.35B 24.68M 2026-03
Stryker USD 22.42B 635M 2025-12
Surmodics USD 111.31M 7.59M 2025-06
Trinity Biotech USD -54.72M 5.18M 2025-09